Company BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Toronto S.E. Other stock markets 02:01:01 2024-05-27 pm EDT			5-day change	1st Jan Change
1.94 ^CAD	-1.52%		-7.62%	-75.13%

May. 20	Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	MT
May. 15	BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	MT

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Companyâs lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patientâs own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyteâs immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patientâs HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

Number of employees: 16

Managers	Title	Age	Since
William Williams CEO	Chief Executive Officer	68	16-10-31
Gadi Levin DFI	Director of Finance/CFO	52	16-01-31
Miguel Lopez-Lago CTO	Chief Tech/Sci/R&D Officer	53	21-04-30
Guiseppe Del Priore CTO	Chief Tech/Sci/R&D Officer	62	22-02-15

Members of the board	Title	Age	Since
Martin Schmieg BRD	Director/Board Member	62	16-05-09
Marc Lustig BRD	Director/Board Member	51	21-08-30
Rebecca Taub BRD	Director/Board Member	71	18-03-06
Vaughn Embro-Pantalony BRD	Director/Board Member	66	19-03-17
William Williams CEO	Chief Executive Officer	68	16-10-31
Jane Gross BRD	Director/Board Member	67	21-10-31
Jamieson Bondarenko CHM	Chairman	39	19-02-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	15,981,726	14,266,886 ( 89.27 %)	0	89.27 %

Name	Equities	%	Valuation
Marc Lustig 15.91 %	2,542,935	15.91 %	6 M $
Lynwood Capital Management, Inc. 9.997 %	1,597,750	9.997 %	4 M $
Lynwood Capital Management, Inc. 9.135 %	1,460,000	9.135 %	3 M $
William Williams 0.9363 %	149,636	0.9363 %	335 185 $
Redmond Asset Management LLC 0.8326 %	133,069	0.8326 %	298 075 $
BMO Bank NA (Investment Management) 0.8236 %	131,620	0.8236 %	294 829 $
Jamieson Bondarenko 0.7500 %	119,856	0.7500 %	268 477 $
KJ Harrison & Partners, Inc. 0.5446 %	87,044	0.5446 %	194 979 $
Onyx Bridge Wealth Group LLC 0.3129 %	50,000	0.3129 %	112 000 $
Summit Trail Advisors LLC 0.2190 %	35,000	0.2190 %	78 400 $

Name	Equities	%	Valuation
Armistice Capital LLC -	375,000	-	353 250 $
Redmond Asset Management LLC -	75,000	-	70 650 $
Osaic Wealth, Inc. -	1,832	-	1 726 $

BriaCell Therapeutics Corp.

Bellevue Centre 235 -15th Street

V7T 2X1, West Vancouver

+604 921 1810

http://www.briacell.com

address BriaCell Therapeutics Corp.(BCT)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.97

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BRIACELL THERAPEUTICS CORP.	-75.13%	26.37M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-0.29%	21.78B
GENMAB A/S	-9.28%	18.09B
WUXI APPTEC CO., LTD.	-41.70%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs